Published on 04/12/2025
Understanding ATMPs and CGT: Terminology Across FDA, EMA, and MHRA
In recent years, the field of cell and gene therapy (CGT) has evolved rapidly, especially concerning regulatory frameworks established by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Understanding the differences and similarities between advanced therapy medicinal products (ATMPs) as classified by the EMA and the broader category of CGT as interpreted by the FDA is critical for engaging successfully in global markets.
This article serves as a comprehensive regulatory tutorial designed for Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC), clinical, and Quality Assurance (QA) leaders. We
1. Regulatory Definitions: ATMPs vs CGT
The terminology related to advanced therapies can often lead to confusion. Thus, clarifying the definitions is essential. According to the EMA, ATMPs are defined as any medicinal products that are based on genes, tissues, or cells, and are intended for human use. They are primarily classified into three categories:
- Gene therapy medicinal products: These involve the administration of a gene to treat a disease.
- Somatic cell therapy medicinal products: These involve the use of cells that have been manipulated to change their biological characteristics.
- Tissue-engineered products: These involve the use of cells and biomaterials to repair or replace damaged tissue.
On the other hand, the FDA categorizes CGT products without a strict classification system akin to the EMA’s ATMP definitions; rather, the FDA focuses on the type of product and its intended use. Hence, CGT includes a broader range of products that consist of human cellular and tissue-based products, gene therapies, and genetically modified organisms aimed at therapeutic purposes.
2. Key Regulatory Frameworks and Guidelines
To effectively navigate the regulation of ATMPs and CGTs, professionals must familiarize themselves with key legislative frameworks and guidance documents in both the U.S. and Europe. In the U.S., the FDA’s regulation of CGT products primarily falls under the Federal Food, Drug, and Cosmetic Act (FDCA).
The FDA has also introduced several accelerated development pathways, including:
- Breakthrough Therapy Designation: Designed to expedite the development of drugs that treat serious conditions and fill an unmet medical need.
- Regenerative Medicine Advanced Therapy (RMAT) Designation: This provides a pathway for expedited review of regenerative medicine therapies that show promise in treating or curing serious conditions.
In contrast, the European Parliament and the Council of the European Union regulate ATMPs through the ATMP Regulation (Regulation (EC) No 1394/2007). This regulation emphasizes the unique nature of ATMPs, which require specific considerations concerning quality, safety, and efficacy. The EMA utilizes the PRIMe scheme to facilitate patient access to promising therapies while ensuring product availability.
3. Quality Considerations and CMC Alignment
When developing ATMPs and CGTs, adherence to quality standards is paramount. The FDA mandates adherence to current Good Manufacturing Practices (cGMP) for all products that fall under its jurisdiction. Compliance with 21 CFR Parts 210 and 211, as well as 21 CFR Part 11 regarding electronic records and signatures, is essential to ensure product safety and efficacy.
The regulatory expectations differ slightly under the EMA, which also emphasizes compliance with quality management principles, specified in the EMA’s guidelines. Here, CMC considerations outline a comprehensive approach to managing quality throughout the lifecycle of ATMPs, including aspects like manufacturing processes, control strategies, and stability studies.
Both authorities expect a clear and thorough CMC documentation process to uphold product integrity. A well-structured CMC strategy will enhance the likelihood of regulatory submissions being accepted in both jurisdictions.
4. Clinical Development and HTA Considerations
Clinical development of ATMPs and CGTs must be tailored to the regulatory landscape in the respective territories. The FDA requires compliance with the Investigational New Drug (IND) application process under 21 CFR Part 312. This mandates intensive preclinical studies to ensure product safety before clinical trials can commence.
In Europe, developers must navigate various phases of clinical trials as delineated by the Clinical Trials Regulation (EU) No 536/2014. This includes obtaining a Clinical Trial Application (CTA) and ensuring ethical review according to the stipulations outlined by the local competent authorities. Furthermore, HTA considerations significantly impact the reimbursement landscape in both jurisdictions. Evidence-based frameworks guide reimbursement decisions, making it essential for product developers to provide robust clinical evidence demonstrating therapeutic value.
5. Expedited Development Pathways and New Initiatives
Both the FDA and EMA are keenly interested in fostering innovation while minimizing the time between product development and patient access. The FDA’s inclusion of strategies like RMAT designation allows developers of potentially life-saving therapies to get quicker access to regulatory pathways, reducing the time needed to advance from IND to market authorization.
Similarly, the EMA offers the PRIME scheme, which provides enhanced support and early dialogue with developers during the product development process. Through these expedited pathways, both agencies resiliently encourage innovative therapies while maintaining rigorous standards for safety and efficacy.
6. Regulatory Alignment Strategies and Best Practices
In an increasingly interconnected global environment, there is a pressing need for manufacturers to develop a global regulatory strategy that encompasses the regulatory requirements of both the U.S. and Europe. Key alignment strategies include:
- Early and Regular Communication: Proactively engaging with regulatory authorities early in the development process can drastically enhance alignment and minimize misunderstandings regarding expectations.
- Documentation Consistency: Maintain coherence in documentation across various regulatory submissions to streamline approvals.
- Real-World Evidence Integration: Utilizing real-world data in clinical trials may offer robust evidence for HTA considerations in both FDA and EMA assessments.
By thoughtfully addressing these considerations and prioritizing regulatory alignment, developers can improve the odds of successfully bringing innovative CGT products to market efficiently and compliantly.
7. Conclusion: Bridging the Gap Between ATMPs and CGT
An understanding of the regulatory definitions and frameworks governing ATMPs and CGTs in the U.S. and Europe is crucial for stakeholders involved in the development of these cutting-edge therapies. By adopting rigorous quality management practices, navigating the complexities of clinical development, and leveraging expedited pathways, the development landscape can become more conducive to innovation.
This tutorial aimed to fortify Regulatory Affairs, CMC, clinical, and QA leaders with the knowledge needed to align their strategies effectively. A goal of shared understanding and pragmatic approaches not only benefits individual organizations but can profoundly impact the landscape of global healthcare delivery.